The Acceptability of the HPV Vaccine Postpartum and With Pediatric Well-child Visits: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
There are a large number of young adult women who have not received any doses of HPV vaccine or are incompletely vaccinated. Recommendation for HPV vaccine could occur during pregnancy with the administration of the vaccine postpartum. Finding a way to make it easy for women to present for vaccination is imperative as this is currently a 3-vaccine series. The investigators are interested in understanding if women would find it acceptable if the investigators discussed and encouraged the vaccine while pregnant with receipt of the vaccine through their child's pediatrician at well-child visits in the postpartum period. The investigators will survey women in the third trimester of pregnancy to determine if they would find this acceptable and follow-up with them after their child's two month pediatric visit to reevaluate their opinion. No doses of the vaccine will be given.
The investigators are also interested in understanding other factors that could affect whether or not women would be interested in receiving the HPV vaccine postpartum. This includes rates of attendance at postpartum visits as well as behavioral, knowledge and demographic characteristics that may be associated with acceptability of receiving the vaccine.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant women at 28 weeks of gestational age or greater
Exclusion Criteria:
- Primary language other than English or Spanish
- Receipt of any prior doses of HPV vaccine.
Study Plan
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability of HPV vaccination
Time Frame: At time of enrollment
|
Estimation of the proportion of women indicating that they would be willing to receive the HPV vaccine postpartum at pediatric well-child visits if offered in the third trimester of pregnancy
|
At time of enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of women attending postpartum visits
Time Frame: At time of follow-up which will occur 8 weeks after delivery. This could occur up to 5 months after enrollment.
|
Estimation of the proportion of women who attend postpartum visits with their obstetric care providers
|
At time of follow-up which will occur 8 weeks after delivery. This could occur up to 5 months after enrollment.
|
|
Estimate of baseline prevalence of prior HPV vaccination in study population
Time Frame: at time of enrollment
|
Participants eligible for participation based on maternal age and gestational age will be screened for prior doses of HPV vaccine by self-report.
Number of participants with self-report of prior HPV vaccination will be recorded and baseline prevalence from our population will be determined.
|
at time of enrollment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Attitudes and beliefs regarding HPV immunization
Time Frame: at time of enrollment
|
This will be assessed using the Carolina HPV Immunization Attitudes and Belief Scale
|
at time of enrollment
|
|
Health Literacy
Time Frame: at time of enrollment
|
Health literacy will be screened using the "Newest Vital Sign" Measure
|
at time of enrollment
|
|
HPV and HPV vaccine Knowledge
Time Frame: at time of enrollment
|
A series of questions will be used to determine baseline knowledge of HPV and HPV vaccination
|
at time of enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kimberly Kilfoyle, MD, University of North Carolina, Chapel Hill
- Study Chair: Lisa Rahandale, MD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 14-2178
- 5T32HD040672-15 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.